1	Differentially expressed circular RNAs in peripheral blood mononuclear cells
2	of PD patients
3	
4	Stylianos Ravanidis <sup>1</sup> , Anastasia Bougea <sup>1,2,3</sup> , Dimitra Karampatsi <sup>1</sup> , Nikolaos Papagiannakis <sup>2,3</sup> ,
5	Matina Maniati <sup>2</sup> , Leonidas Stefanis <sup>2,3</sup> , Epaminondas Doxakis MSc <sup>1</sup>
6	
7	Centers of <sup>1</sup> Basic Research and <sup>2</sup> Clinical Research, Biomedical Research Foundation, Academy
8	of Athens, Athens, 11527, Greece.
9	<sup>3</sup> First Department of Neurology, National and Kapodistrian University of Athens Medical School,
10	Athens, 11528, Greece.
11	
12	Corresponding author: Epaminondas Doxakis
13	Corresponding author's address: Center of Basic Research, Biomedical Research Foundation,
14	Academy of Athens, Soranou Efesiou 4, Athens, 11527, Greece.
15	Corresponding author's phone +30-2106597479, Fax: +30-2106597545
16	Corresponding author's e-mail address: edoxakis@bioacademy.gr
17	
18	

## 19 ABSTRACT

#### 20 Background

21 New noninvasive and affordable molecular approaches that will complement current practices and

22 increase the accuracy of PD diagnosis are urgently needed. CircRNAs are highly stable non-coding

23 RNAs that accumulate with aging in neurons and are increasingly shown to regulate all aspects of

24 neuronal development and function.

25 <u>Objectives</u>

26 The aims of the present study were to identify differentially expressed circRNAs in PBMCs of

27 idiopathic PD patients and explore the competing endogenous RNA networks affected.

28 <u>Methods</u>

Eighty-seven circRNAs were initially selected based on relatively high gene expression in the human brain. Over half of these were readily detectable in PBMCs using RT-qPCR. Comparative expression analysis was then performed in PBMCs from sixty controls and sixty idiopathic subjects with PD.

33 <u>Results</u>

Six circRNAs derived from MAPK9, HOMER1, SLAIN1, DOP1B, REPS1, and PSEN1 transcripts were significantly downregulated in PD patients. The classifier that best distinguished PD consisted of four circRNAs with an AUC of 0.84. CLIP-Seq data revealed that the RNA binding proteins bound by most of the deregulated circRNAs include the neurodegenerationassociated FUS, TDP43, FMR1 and ATXN2. MicroRNAs predicted to be sequestered by most deregulated circRNAs had the GOslim categories 'Protein modification', 'Transcription factor activity' and 'Cytoskeletal protein binding' mostly enriched.

41 <u>Conclusions</u>

This is the first study that identifies circRNAs deregulated in the peripheral blood of PD patients.
They may serve as diagnostic biomarkers and since they are highly expressed in the brain and are
derived from genes with essential brain functions, they may also hint on the PD pathways affected.

# 46 **INTRODUCTION**

The diagnosis of PD is currently based on clinical diagnostic criteria and neuroimaging and is monitored by rating scales related to motor and non-motor features <sup>1</sup>. Rating scales are frequently subjective and influenced by periodic fluctuations in symptoms and effective symptomatic therapies, while neuroimaging techniques, such as DAT-SPECT, offer a quantifiable measure of disease progression but are limited by practicality and costs <sup>2</sup>. In addition, protein biomarkers, such as those based on alpha-synuclein (SNCA) and dopamine metabolic products have yielded mixed results, do not reflect disease progression and require an invasive lumbar puncture <sup>3</sup>.

54 Circular RNAs (circRNAs) are a newly recognized class of single-stranded regulatory RNAs that 55 are formed by head-to-tail splicing in which a downstream 5' splice site is covalently connected to an upstream 3' splice site of an RNA molecule. The result is an enclosed non-polyadenylated 56 circular transcript <sup>4-6</sup>. Due to the lack of free ends, that are normally targeted by 3' and 5' 57 58 exoribonucleases, circRNAs are extremely stable with half-life of more than 48 h compared to approximately 6 h of linear transcripts <sup>7, 8</sup>. There are different subtypes of circRNAs including 59 60 exonic, intronic and exo-intronic. Exonic circRNAs are mostly localized in the cytoplasm where 61 they act as sponges for microRNAs (miRNAs) and RNA-binding proteins (RBPs), thus inhibiting their interaction with mRNA targets <sup>4,9-11</sup>. In contrast, intronic or exo-intronic circRNAs are mostly 62 63 localized in the nucleus and have few or no binding sites for miRNAs; instead they function to control transcription <sup>12, 13</sup>. Interestingly, the co-transcriptional biogenesis of circRNAs has also 64

been shown to reduce linear host mRNA levels and change downstream splice-site choice in some
 mRNAs <sup>11, 14, 15</sup>.

CircRNAs are widely conserved and more abundant in the brain than in any other tissue <sup>16</sup> with many being expressed in an organ-specific manner, along with their host genes which are enriched with tissue-specific biological functions <sup>17</sup>. For instance, brain circRNA host genes are enriched in neurotransmitter secretion, synaptic activities and neuron maturation <sup>17</sup>. Importantly, however, they are regulated independently from their linear counterparts <sup>16, 18</sup> with 60% of CNS circRNAs being upregulated throughout development, especially during synaptogenesis, while only 2% of their linear isoforms show this tendency <sup>17</sup>.

Recent studies revealed the deregulation of circRNAs in neurodegenerative diseases and 74 neuropsychiatric disorders (reviewed in <sup>19</sup>). Furthermore, several brain-enriched circRNAs have 75 been associated with pathogenetic processes of neurodegeneration. For instance, CDR1as (ciRS-76 7), a highly abundant circRNA in the brain, is downregulated in the brain of patients with AD  $^{20}$ . 77 This circRNA contains 63 binding sites for miR-7 and therefore it is acting as an efficient sponge 78 for it <sup>4</sup>. Importantly, critical proteins for the neurodegeneration processes such as the ubiquitin 79 protein ligase A (UBE2A), which catalyses the proteolytic clearing of toxic amyloid peptides in 80 AD, and SNCA, which accumulates in PD/AD, are both targets of miR-7<sup>21, 22</sup>. More recently, 81 another circRNA, circSLC8A1, was found to increase in the substantia nigra of individuals with 82 PD and in cultured cells exposed to the oxidative stress-inducing agent paraquat <sup>23</sup>. Importantly, 83 84 circSLC8A1 carries seven binding sites for miR-128, an abundant and brain-restricted miRNA that governs neuronal excitability and motor behavior <sup>24-27</sup>. 85

Peripheral blood mononuclear cells (PBMCs) inherit the same genetic information as brain cellsand are armed with abundant signaling pathways that respond to pathological changes. Multiple

studies have shown that genome-wide transcriptional and alternative splicing profiles in peripheral 88 blood parallel changes in gene expression in the brain, reflecting broad molecular and cellular 89 impairments <sup>28-33</sup>. Therefore, PBMCs provide a powerful and minimally-invasive tool for the 90 identification of novel targets for neurodegeneration research. Considering that circRNAs a) are 91 abundant in the brain modulating gene expression *en masse*, b) are stable, c) do not get modified 92 93 like proteins, hence levels directly correlate with activity and d) can be accurately quantified by routine and fast laboratory methods, such as RT-qPCR, suggests that they not only represent 94 95 excellent candidate biomarkers but also important constituents of the pathophysiological processes implicated in neurological diseases. The purpose of this study was to identify differentially 96 expressed brain-enriched circRNAs in PBMCs from patients with idiopathic PD (iPD) and 97 pinpoint competing endogenous (ceRNA) networks. 98

99

#### 100 MATERIAL AND METHODS

#### 101 Figure 1 provides a schematic representation of the workflow.

102

## **103** Study population

The present study included 60 iPD patients and 60 healthy individuals in two separate cohorts. Patients were assessed with brain magnetic resonance imaging (MRI) or computed tomography (CT) and no relevant brain vascular lesions explaining the clinical phenotype were detected. The control group included spouses or unrelated companions of patients who had no known neurological disease, comorbidities or PD family history. Individuals with concurrent malignant tumours, psychiatric disorders, collagen diseases, endocrine and cardiovascular diseases, or infections were excluded from this study, since these conditions are expected to alter the

expression profile of transcripts. Patients affected by atypical parkinsonism were also excluded. 111 All patients and controls were recruited from the National and Kapodistrian University of Athens' 112 First Department of Neurology at Eginition hospital. PD was diagnosed by two neurologists 113 according to Postuma et al., criteria<sup>1</sup>. In all cases, essential demographic and clinical information, 114 including the study questionnaire for motor and non-motor manifestations of the disease, rating 115 116 scales [Hoehn & Yahr (H&Y) stage, mini-mental state examination (MMSE, cognitive impairment score <26<sup>34</sup>), Unified Parkinson's Disease Rating Scale part III (UPDRS III) in the on or off state] 117 118 were collected and documented. The demographic and clinical features of patients and controls 119 are summarized in Table 1. Levodopa equivalent daily dose (LEDD) was calculated for the patient group according to Tomlinson et al., criteria<sup>35</sup>. The Eginition hospital and BRFAA ethics 120 committees approved the study and all participants provided written consent. 121

122

## 123 Isolation of peripheral blood mononuclear cells

124 PBMCs were isolated from whole blood by employing density-gradient centrifugation using the

125 Biocoll Separating Solution according to manufacturer's instructions (Biochrom AG).

126

#### 127 Total RNA extraction and RT-qPCR analysis

Total RNA extraction was performed using the RNAzol®-RT reagent according to manufacturer's
instructions (Molecular Research Center, MRC). To improve the yield of the small RNA fraction,
a polyacryl carrier (PC152, MRC) was added during the extraction method. Reverse transcription
reactions were performed in triplicate for every sample. Similarly, qPCR was performed in
triplicate on the Roche Lightcycler<sup>®</sup> 96 using the SYBR FAST Universal 2X qPCR Master Mix
from Kapa Biosystems. For the differential expression analysis, we selected only those circRNAs

134	that were detected in PBMCs with a crossing threshold (Ct) value below 30, for improved detection
135	accuracy. All primers span the splice junction. U6 and GAPDH were used as reference genes. The
136	relative expression level of circRNAs was calculated using the $2^{-\Delta\Delta Ct}$ method between age- and
137	gender- matched counterparts. Primer sequences can be found in Suppl. Table 1.

138

## 139 CircRNA selection process

Eighty-seven circRNAs were carefully selected by cross-examining the data from three genome-140 wide surveys <sup>4, 18, 36</sup>. We chose circRNAs that had high expression in the brain (Rybak-Wolf score 141 142 above ~1,000) and low or no expression in other tissues. The host gene expression was also taken into account in the selection process. Initially, based on GTEx portal expression data, circRNAs 143 for which host transcripts were specifically expressed in the brain were selected. However, we 144 found that many circRNAs derived from these transcripts were not readily detectable in PBMCs. 145 146 We, therefore, widened the analysis to host transcripts that are brain- or at least cerebellum-147 enriched (i.e. not exclusively expressed in the brain). Last, we included six brain-abundant circRNAs deriving from host transcripts with low expression in the brain (UBXN7\_circ\_0001380, 148 TMEM138 circ 0002058, ZNF292 circ 0004058, HAT1 circ 0008032, 149 150 ZFAND6 circ 0000643, UIMC1 circ 0001558) and eight circRNAs that are hosted by brainrelevant transcripts that have been found deregulated in AD (CORO1C\_circ\_0000437, 151 37 152 WDR78\_circ\_0006677, PHC3\_circ\_0001359, SLAIN2\_circ\_0126525) and autism 153 (FAM120A circ 0001875, CSNK1G3\_circ\_0001522, VMP1 circ 0006508, SMARCA5 circ 0001445)<sup>38</sup>. For the list of circRNAs analyzed see Suppl. Tables 1 and 2. 154 155

#### 156 **CircRNA target network**

The interactions of the differentially expressed circRNAs with miRNAs and RBPs were identified by obtaining data from the Circular RNA Interactome (CircInteractome) and Interactional Database of Cancer-Specific CircRNAs (IDCSC) databases, respectively <sup>39, 40</sup>. CircInteractome utilizes the TargetScan algorithm to predict microRNA response elements (MREs, ie miRNAbinding sites) while IDCSC hosts circRNA cross-linking immunoprecipitation (CLIP)-Seq data for the different RBPs extracted from StarBase database <sup>41</sup>. The circRNA-miRNA and circRNA-RBP interactomes were then manually curated using the Cytoscape v.3.8.0 platform.

164

## 165 miRNA pathway analysis

The DIANA mirPath v.3 software suite was used to identify miRNA-regulated pathways. This 166 software renders possible the functional annotation of miRNAs using standard hypergeometric 167 distributions, unbiased empirical distributions and meta-analysis statistics <sup>42</sup>. Here, predicted 168 targets from DIANA microT-CDS algorithm with high quality experimentally supported 169 interactions were used to identify KEGG molecular pathways, as well as GO terms targeted by 170 each miRNA. The combinatorial effect of deregulated miRNAs was identified by simultaneously 171 selecting multiple miRNAs in the software. The default values (p-value threshold 0.05, microT-172 173 CDS threshold 0.8, FDR correction option ticked) were used for the analysis.

174

#### 175 Statistical analysis

Statistical analysis was performed using GraphPad PRISM v5.0 and R v3.5.3. All data underwent
a normality test (Shapiro–Wilk), and were found to be non-normally distributed. As a result, all
circRNA data underwent a logarithmic transformation (with base 2), in order to better approximate
the normal distribution. The parametric t-test was used to observe differences between healthy

controls and PD patients. We applied the Benjamini – Hochberg false discovery rate correction in 180 the resulting p-values to account for the multiple number of tests. Spearman's method with 181 182 Bonferroni correction for multiple comparisons was used to correlate circRNA expression levels with participants' demographic and clinical characteristics (p-value threshold 0.0005). 183 To assess the possibility that sex is a confounding factor, the two-way ANOVA model was applied 184 185 to the log-transformed data (normally distributed) with sex as an additional factor. No difference in the circRNAs that were statistically significant was found. 186 187 Receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated to evaluate the predictive sensitivity and specificity of PBMC circRNAs for 188 PD diagnosis. The cutoff value for the ROC analysis was determined using the Youden Index. 189 Data are presented as means  $\pm$  SEM. circRNA selection was based on the stepwise removal 190 approach. A logistic regression statistical model containing all available circRNAs as independent 191 192 variables and PD status as the dependent variable was built. Then, the circRNAs with the least 193 contribution in the model (as determined by an F test) were removed. This process continued until 194 no further removals were possible.

195

#### 196 Data availability

197 The datasets analysed during the current study are all available from the corresponding author on198 request.

199

200 **RESULTS** 

# 201 circRNAs are differentially expressed in PBMCs of idiopathic PD patients

The demographic and clinical characteristics of 60 healthy controls and 60 iPD patients are 202 summarized in Table 1. The mean age of 64.5 and the sex ratio were the same for both groups. 203 The disease duration for the PD group was  $4.8\pm0.55$  years and the MMSE score  $27.5\pm0.56$ . 204 Initially, RT-qPCR was employed to detect plasma levels of 32 circRNAs that are highly-205 expressed by brain cells. It was anticipated that a sufficient quantity of brain-derived circRNAs 206 207 would find its way into the plasma. However, only two circRNAs, RMST (at Ct 29) and PSD3 (at Ct 28), were detected. Using the same amount of RNA, this time extracted from human brain 208 209 tissue, it was revealed that all circRNAs were readily detectable with an average Ct value of 26, 210 demonstrating that all primer pairs were functional (data not shown). This indicated that brainenriched circRNAs are not as abundant as brain-enriched miRNAs (average Ct value of 17.5 for 211 21 brain-enriched miRNAs in the same human brain total RNA) and are not circulating in 212 appreciable amount in the blood (average Ct value for the corresponding miRNAs in the plasma 213 is 25) <sup>43</sup>. 214

Based on previous studies showing that genome-wide transcriptional and alternative splicing profiles in peripheral blood cells parallel changes in gene expression in the brain, the levels of circRNAs were next assessed in PBMCs. We increased the number of primer sets to 87 and found that 48 were detected with a Ct value below 30, safeguarding accurate and reproducible detection. These circRNAs were then analyzed for differential expression in healthy control and iPD patient samples (Suppl. Table 3).

Following multiple comparison adjustment, six circRNAs were significantly altered in the PBMCs
obtained from PD patients compared to healthy controls. MAPK9\_circ\_0001566,
HOMER1\_circ\_0006916, SLAIN1\_circ\_0000497, DOP1B\_circ\_0001187,
RESP1\_circ\_0004368, and PSEN1\_circ\_0003848 were all downregulated in the PD cohort (Fig.

225	2 and Suppl. Table 3). The swarm plots for the 42 circRNAs whose relative expression was not
226	significantly altered in the PBMCs of idiopathic PD patients are shown in Supplemental Fig 1.
227	
228	Association between circRNA levels and clinical features, age or sex
229	Spearman correlation test was used to relate circRNA levels to iPD patients' clinical features. We
230	found no correlation between age-at-onset, disease duration, UPDRS III, MMSE, LEDD, H&Y or
231	patients' on/off state and circRNA levels (Suppl. Table 4 and data not shown). Finally, correcting
232	clinical scores with LEDD did not reveal any more associations (data not shown). In addition,
233	there was no significant correlation between circRNA expression and age or sex in either healthy
234	controls or PD patients.
235	
236	Discriminant Analysis
236 237	<b>Discriminant Analysis</b> To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy
236 237 238	<b>Discriminant Analysis</b> To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four
236 237 238 239	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and
236 237 238 239 240	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC
236 237 238 239 240 241	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3).
236 237 238 239 240 241 242	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3).
236 237 238 239 240 241 242 243	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3). CeRNA networks
236 237 238 239 240 241 242 243 244	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3). CcRNA networks CircRNAs can act as miRNA and RBP sponges for regulating gene expression. To explore the
236 237 238 239 240 241 242 243 243 244 245	Discriminant Analysis To evaluate the utility of PBMC circRNA levels in discriminating subjects with iPD from healthy controls, ROC curve analysis was performed. The diagnostic sensitivity and specificity of a four circRNA panel (SLAIN1_circ_0000497, SLAIN2_circ_0126525, ANKRD12_circ_0000826, and PSEN1_circ_0003848) were 75.3% (62.1-85.2%) and 78% (65.8-88%), respectively, and the AUC was 0.84 (Fig. 3). CeRNA networks CircRNAs can act as miRNA and RBP sponges for regulating gene expression. To explore the functional role of the deregulated circRNAs we identified all their miRNA and RBP targets.

247 MAPK9\_circ\_0001566 having the most of MREs (38 and 24, respectively) (Fig. 4A).

Interestingly, five miRNAs were predicted to be sponged by half or more of the deregulated PD circRNAs. miR-526b and miR-659 are the top targets, sequestered by four deregulated PD circRNAs (Fig. 4A). Fig. 4B shows the deregulated circRNA-RBP network. Like for miRNAs, CLIP-Seq data obtained from StarBase database revealed that the deregulated circRNAs have multiple RBP binding sites. MAPK9\_circ\_0001566 and HOMER1\_circ\_0006916 host the most of these sites with 60 and 49 sites, respectively. Interestingly, 29 RBPs were sequestered by four or more deregulated circRNAs.

255

#### 256 CircRNA-miRNA pathway analysis

In order to explore the biological pathways affected by the five miRNAs (miR-516b-5p, miR-257 526b-5p, miR-578, miR-659-3p, and miR-1197) mostly sequestered by three or more of the 258 259 deregulated circRNAs, the DIANA mirPath v3 tool was used to align miRNA predicted targets 260 with KEGG pathways and GOslim categories. A Priori gene union analysis of deregulated miRNA 261 targets revealed fourteen KEGG categories as significantly enriched; they included 'Thyroid hormone signaling pathway' (p < 0.0015, 24 genes), 'Regulation of actin cytoskeleton' (p < 0.015, 262 42 genes) 'Phosphatidylinositol signaling pathway' (p < 0.016, 16 genes), 'MAPK signaling 263 264 pathway' (p < 0.016, 46 genes) and 'FoxO signaling pathway' (p < 0.016, 26 genes) (Suppl. Table 5A). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2A). Thirty-nine 265 266 GOslim categories that are controlled by the gene union of the deregulated miRNA targets were 267 enriched following a Priori analysis; these included 'Cellular protein modification' (p < 3.93E-19, 283 genes), 'Nucleic acid binding transcription factor activity' (p< 7.74E-07, 112 genes), 268 269 'Cytoskeletal protein binding' (p< 3.91E-09, 102 genes) 'Cell death' (p< 7.91E-08, 112 genes),

'RNA binding' (p< 6.93E-07, 207 genes) and 'Response to stress' (p< 3.72E-05, 225 genes)</li>
(Suppl. Table 5B). Similar findings were obtained using a Posteriori analysis (Suppl. Fig. 2B).

272

#### 273 **DISCUSSION**

We profiled brain-enriched circRNAs in peripheral blood from controls and patients with PD using 274 a RT-qPCR -based approach for three reasons. First, primers could be designed to span the splicing 275 276 junction which guarantees that only message from the circRNA is amplified. Second, RT-qPCR is 277 the most sensitive method to accurately determine expression changes between cohorts; the alternative microarray approach is prone to errors at multiple levels and nearly always requires a 278 279 follow up RT-qPCR-based analysis to validate findings. Third, we probed circRNAs that are abundantly expressed in the brain; in this way, we could identify differentially expressed or spliced 280 circRNAs that are more likely associated with the neurological processes of PD. 281

#### 282 Insights into the differentially expressed circRNA genes

We initiated our study with 87 brain-enriched circRNAs from which over half were confidently detected in PBMCs. From these circRNAs, six were differentially expressed in PD with a 17% decrease on average from healthy controls levels. These changes may appear subtle but depending on the circRNA baseline expression levels and considering the relative importance of their multiple targets (transcription factors, RBPs, and miRNAs) as well as the added-up deregulation of the common targets, the biological outcome is expected to be significant.

It has been observed that the biological role of host transcripts reflects on the function of the circRNAs <sup>17</sup>. We found that the host transcripts of the differentially-expressed circRNAs are not exclusive to brain pathways; rather, they are house-keeping genes, whose functions are best

characterized in the CNS as they are essential for neuronal homeostasis. A brief bibliographicaloverview of their properties is described below.

Hsa\_circ\_0001566 is hosted by the mitogen-activated protein kinase 9 (MAPK9) gene. 294 MAPK9/JNK2 is a member of the c-Jun n-terminal kinase 1-3 family robustly activated by 295 environmental stresses, including the PD-related neurotoxins lipopolysaccharides (LPS), MPTP 296 and 6-hydroxydopamine (6-OHDA) to mediate neuronal degeneration <sup>44</sup>. It is indispensable during 297 298 brain development for neuronal migration, axonal sprouting and guidance, as well as neuronal survival <sup>45</sup>. Hsa\_circ\_0006916 is hosted by the homer scaffold protein 1 (HOMER1) gene. 299 300 HOMER1 is a member of Homer 1-3 family constituting important scaffold proteins at the postsynaptic density that associate with a large number of Ca<sup>2+</sup>-handling proteins, including 301 channels, receptors, and shank scaffolding proteins to regulate intracellular Ca<sup>2+</sup> homeostasis <sup>46</sup>. 302 An SNP in the promoter of HOMER1 has been associated with psychotic symptoms in PD<sup>47</sup>. 303 Further, circHomer1a is reduced in the prefrontal cortex of patients with schizophrenia and bipolar 304 disorder, where it modulates the alternative splicing of mRNA transcripts involved in synaptic 305 plasticity and psychiatric disease <sup>11</sup>. Hsa\_circ\_0000497 is hosted by the SLAIN motif family 306 member 1 (SLAIN1) gene. SLAIN1 and 2 are microtubule-associated proteins that promote 307 308 persistent microtubule growth by recruiting the microtubule polymerase ch-TOG to microtubule plus-ends and thus they are important for axon elongation in developing neurons <sup>48</sup>. Recently, 309 SLAIN1 was identified as a candidate gene for intellectual disability <sup>49</sup>. Hsa\_circ\_0001187 is 310 311 hosted by the DOP1 leucine zipper like protein B (DOP1B) gene. DOP1B/ DOPEY2/ C21orf5 and its ortholog DOP1A interact with partner MON2 to retrograde transport endosomes from the TGN 312 to the Golgi <sup>50, 51</sup>. DOP1B is a candidate gene for mental retardation in Down syndrome <sup>52, 53</sup> and 313 copy number variations (CNVs) have been observed in AD <sup>54, 55</sup>. Hsa\_circ\_0004368 is hosted by 314

the RALBP1 associated eps domain containing 1 (REPS1) gene. REPS1 is a signaling and 315 endocytosis adaptor that interacts with adaptor Intersectin 1 (ITSN1) in clathrin-coated pits and 316 Amphiphysin 1 (AMPH) at the surface of synaptic vesicles <sup>56</sup>. Mutations in REPS1 are associated 317 with neurodegeneration with brain iron accumulation (NBIA) in the basal ganglia <sup>57</sup>. 318 Hsa circ 0003848 is hosted by the presenilin 1 (PSEN1) gene. PSEN1 and its paralog PSEN2 are 319 320 the endoprotease subunits of the gamma-secretase complex that catalyses the intramembrane 321 cleavage of integral membrane proteins such as Notch receptors and amyloid-beta precursor protein (APP). Mutations in either gene cause early-onset AD  $^{58}$  and  $\alpha$ -synuclein accumulation in 322 LB in these patients <sup>59</sup>. Besides their established role in mediating the formation of A $\beta$  peptide, 323 more recently mutant PS1 has been shown to impair numerous cellular functions such as calcium 324 flux, organization of proteins in different compartments, and protein turnover via vacuolar 325 326 metabolism <sup>60</sup>. Interestingly, a novel PSEN1 mutation was recently identified as the likely cause for early-onset Parkinsonism<sup>61</sup>. 327

## 328 Correlation between circRNA levels and demographics

There was no significant correlation between the differential expression of a particular circRNA and clinical or demographic measures. Combined interactions with age and sex did not also appear to affect circRNA levels. These findings reinforce current knowledge that the etiology of PD is complex involving a mix of genetic and environmental influences on ageing brain. Similar findings have been observed in miRNA studies <sup>62</sup>. Further, a pool of four circRNAs discriminated subject with PD from controls with an AUC of 0.84.

## 335 CircRNA-RBP and circRNA-miR interactions

*In silico* approaches were utilized to identify potential biological roles for the deregulated
 circRNAs by identifying the RBPs and miRNAs that are sequestered preferentially by them. Since

the circRNAs were all downregulated, it indicates that target RBP and miRNA functions will be
enhanced in PD. The circRNA-RBP network which is based on experimental CLIPS-seq data
revealed that 29 RBPs were bound by four or more deregulated circRNAs. Importantly, several of
these RBPs are implicated in familial neurodegeneration including Fragile X Mental Retardation
Protein 1 (FMR1, Fragile X syndrome and associated disorders), Ataxin 2 (ATXN2,
Spinocerebellar ataxia 2, late-onset PD), Fused in Sarcoma (FUS) and TAR DNA binding protein
(TARDBP/TDP43) (Amyotrophic lateral sclerosis, Frontotemporal dementia) <sup>63-72</sup>.

345 The circRNA-miRNA network revealed five miRNAs that were predicted to be sponged by at least 346 three downregulated PD circRNAs. miR-659-3p is of particular interest as it targets progranulin (PGRN), a neuroprotective and anti-inflammatory protein implicated in FTD <sup>73-77</sup>. To explore the 347 molecular pathways controlled by the five miRNAs, in silico analysis of KEGG pathways and 348 GOslim terms was performed. KEGG categories revealed multiple signaling pathways (Thyroid 349 350 hormone, Phosphatidylinositol, MAPK, FoxO) implicated in neuronal survival and plasticity and 351 'Regulation of actin cytoskeleton' which is central to pre- and postsynaptic assembly as overrepresented <sup>78-81</sup>. GOslim analysis revealed 'Cellular protein modification', 'Nucleic acid binding 352 transcription factor activity', 'Cytoskeletal protein binding', 'Cell death', and 'Response to stress' 353 354 as overrepresented among the biological processes affected. 'Cellular protein modifications' such as phosphorylation, ubiquitination, truncation, acetylation, nitration and sumoylation of PD-linked 355 proteins have emerged as important modulators of pathogenic mechanisms in PD<sup>82, 83</sup>. 356 357 'Transcription factor' changes indicate that there is not only misexpression at the mRNA 358 translation level by miRNA deregulation, but that there exists a second wave of en masse 359 deregulation involving transcription-mediated changes. Finally, deregulation of fine cytoskeletal 360 dynamics is expected to impair trafficking and intracellular signaling pathways and has been

recognized as a key insult in the pathogenesis of multiple neurodegenerative diseases including
 PD <sup>84, 85</sup>.

363 Conclusions

We performed an RT-qPCR-based analysis on RNA extracted from PBMC cells from a cohort of 364 patients with PD and matched controls to identify deregulated circRNAs. The circRNAs 365 366 investigated are highly-expressed in the human brain. This is the first study of its kind in PD. The 367 measurement of four out of six downregulated circRNAs provided reasonable sensitivity and 368 specificity for PD in this discovery cohort. The circRNAs found deregulated form a robust set of 369 brain-associated circRNAs, that can now be further evaluated, along with other measures, as diagnostic and possible therapeutic targets for PD. In silico analysis provided a comprehensive 370 guide of the pathways and processes they control, shedding light on their potential biological role. 371 The impact of these findings will now await further exploration. 372

373

#### 374 ABBREVIATIONS

6-OHDA, 6-hydroxydopamine; ANCOVA, analysis of covariance; ANOVA, analysis of variance; 375 APP, amyloid-beta precursor protein; AUC, area under the curve; circRNA, circular RNA; CT, 376 377 computed tomography; DOP1B, DOP1 leucine zipper like protein; FTD, Frontotemporal dementia; GO, gene ontology; H&Y, Hoehn & Yahr; HC, healthy control; HDAC, histone 378 379 deacetylase; HOMER1, homer scaffold protein 1; hsa, homo sapiens; iPD, idiopathic PD; KEGG, 380 Kyoto encyclopedia of genes and genomes; LEDD, Levodopa equivalent daily dose; LPS, lipopolysaccharides; MAPK9, mitogen-activated protein kinase 9; MMSE, Mini Mental State 381 382 Examination; MRI, magnetic resonance imaging; NBIA, neurodegeneration with brain iron 383 accumulation; PD, Parkinson's disease; PSEN1, presenilin 1; REPS1, RALBP1 associated eps

domain containing 1; SNCA, alpha-synuclein; SLAIN1, SLAIN motif family member; UPDRS,
unified Parkinson's disease rating scale; TARDBP, TAR DNA Binding Protein; UTR,
untranslated region.

387

## 388 ACKNOWLEDGMENTS

389 The authors are grateful to patients, relatives, and volunteer healthy controls for their participation 390 in this study. This research was financed by Greece and European Union (European Social Fund-391 ESF) through the Operational Program «Human Resources Development, Education and Lifelong 392 Learning 2014-2020» in the context of the project "Development of diagnostic biomarker tests for Parkinson's disease" (MIS 5049385). It was also co-financed by the action "Precision medicine 393 Hellenic network in genetic neurodegenerative diseases" ( $2018\Sigma E01300001$ ) of the Hellenic 394 public investments program of GSRT and the Michael J. Fox Foundation for Parkinson's Research 395 (Grant ID 13353). 396

397

#### 398 AUTHORS' ROLES

Conceived the study: ED. Neurologically examined patients: AB, NP, LS. Peripheral blood
processing: MM. Differential expression analysis: SR, DK, ED. Analyzed data: SR, NP, ED.
Bioinformatics analyses: ED. Wrote the manuscript: ED. All authors read, edited and approved
the final manuscript.

403

## 404 FINANCIAL DISCLOSURES

405 **Stylianos Ravanidis:** SR is a postdoctoral researcher at BRFAA. No Disclosures.

406 Anastasia Bougea: AB is a neurology resident at Eginition Hospital. No Disclosures.

- 407 **Dimitra Karampatsi:** DK is a former MSc student at BRFAA. No Disclosures.
- 408 **Nikolaos Papagiannakis:** NP is a neurology resident at Eginition Hospital. No Disclosures.
- 409 **Matina Maniati:** MM is a technician at BRFAA. No Disclosures.
- 410 Leonidas Stefanis: Leonidas Stefanis is employed by the National and Kapodistrian University
- 411 of Athens and the Biomedical Research Foundation of the Academy of Athens. He has the
- following active grants: Fondation Sante research grant, a Michael J. Fox Foundation grant as a
- 413 collaborator and an ELIDEK grant. He has served on an Advisory Board for Abbvie, Novartis and
- 414 Roche and has received honoraria from Abbvie and Sanofi.
- 415 **Epaminondas Doxakis:** ED is employed by BRFAA. He has one active MJFF research grant.
- 416

418

# 417 **FIGURES**



419 Figure 1. Schematic representation of the workflow.







and idiopathic PD cohorts. Mean levels +/- SEM are included below each graph. Graphs
demonstrate relative expression of log-transformed data. Unpaired t-test was used to determine the
significance of differences between the two groups. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.</li>

425



Figure 3. The receiver operating characteristic (ROC) curve analysis for discriminating
idiopathic PD from healthy control subjects. ROC curve of four circRNAs
(MAPK9\_circ\_0001566, SLAIN1\_circ\_0000497, SLAIN2\_circ\_0126525, and
PSEN1 circ 0003848) differentiate iPD from HC cases.



431

432 Figure 4. CircRNA target networks. Diagrams show (A) the predicted miRNAs and (B) the

433 CLIP-Seq identified RBPs that bind to differentially expressed circRNAs.

434

## 436 SUPPLEMENTAL FIGURES









440

Supplemental Figure 1. Swarm plots for the 42 circRNAs whose relative expression is not
significantly altered in the PBMCs of idiopathic PD patients. Mean levels +/- SEM are included
below each graph. Graphs demonstrate relative expression of log-transformed data. Unpaired ttest was used to determine the significance of differences between the two groups. \*p<0.05,</li>
\*\*p<0.01, \*\*\*p<0.001.</li>

446





Supplemental Figure 2. KEGG and GOslim classifications of the circRNA-miRNA target
genes. (A) KEGG and (B) GOslim categories union of the RNA targets of the five miRNAs

450 sequestered by three or more of the deregulated PD circRNAs (miR-516b-5p, miR-526b-5p, miR-

451 578, miR-659-3p, miR-1197). They were prepared using the DIANA-miRPath v3.0 interface using

452 default values (p-value threshold 0.05, microT-CDS threshold 0.8).

453

# **TABLES**

# **Table 1. Demographic and clinical profiles of healthy controls and PD patients.**

Variables	Healthy controls	iPD	<i>P</i> value
No of subjects	60	60	N/A
Age <sup>a</sup>	$64.38 \pm 1.335$	$64.73 \pm 1.33$	0.84
Sex (M/F)	29/31	29/31	1
Age of onset <sup>a</sup>	N/A	$59.95\pm10.97$	N/A
<b>Disease duration</b> <i>a, b</i>	N/A	$4.78\pm0.55$	N/A
UPDRS III a, c	N/A	$25.77 \pm 1.92$	N/A
(on/off state)		(42/18)	
MMSE <sup>a, d</sup>	N/A	$27.53\pm0.56$	N/A
<b>H&amp;Y</b> <sup><i>a</i>, <i>e</i></sup>	N/A	$1.82\pm0.10$	N/A
LEDD <sup><i>a, f</i></sup>	N/A	$496.9\pm59.71$	N/A

 $a \pm SD.$ 

- 460 <sup>b</sup> Disease duration is counted in years.
- 461 <sup>c</sup> Unified Parkinson's Disease Rating Scale.
- 462 <sup>d</sup> Mini Mental State Examination.
- 463 <sup>*e*</sup> Hoehn & Yahr.
- f Levodopa equivalent daily dose.

# 467 SUPPLEMENTAL TABLES

468

# 469 Supplemental Table 1. Primer sequences used for real-time PCR.

circRNA	Forward	Reverse
hsa_AFF2_circ_0001947	ACTGCCAAAGTTCACCATCC	AGTTTCCAAGCGTGTTCTGG
hsa_AGTPBP1_circ_0007162	GTGGATTCGTATGGGGACTG	CCTGCCGTAGGAACAACAAT
hsa_ANKRD12_circ_0000826	CGTCCAGTGGATGTAGCAGA	AACCCAGATTTGGGCATTTT
hsa_ANKS1B_circ_0007294	TGGGAAAAATGGAAGCCAGAGT	AGAACTCGTACAACATCCACCT
hsa_ARPP21_circ_0001281	GTCCATCGAGTGGCAGCTT	ATGCCCATCTCCATGCGATT
hsa_ATP6V0A1_circ_0043837	CGCCGTCAGTATTTGAGGAG	GGCTGACTCCAAACAGCATA
hsa_BACH1_circ_0001181	CGCTGTCGCAAGAGAAAAC	AGGCAAAAACCGAGTTCTCA
hsa_CDR1_circ_0001946	CATGTCTTCCAACGTCTCCA	ACCTTGACACAGGTGCCATC
hsa_CNTNAP2_circ_0133631	GGATGCTCTACAGCGACACA	GGGAGTCCAGAGACAAGTGG
hsa_CORO1C_circ_0000437	ATGGGTTACATGCCCAAGAG	ACACCCCATTGCTAGTGTCC
hsa_CSNK1G3_circ_0001522	GCACCACAGCTACATTTGGA	GCATGTTCATCCCATTCGT
hsa_DAB1_circ_0113684	TGTGCCAAAAAGTCAACCTG	CCCGGTGATCTGTAATGTCC
hsa_DGKB_circ_0133622	AGGAGACCCAGTGCCTTACA	GGTCCTTCAAAGGTCCACAG
hsa_DNAJC6_circ_0002454	TGACATTCGAAGCTTTTTGG	ATAGCTGGGCTCCATGTCTG
hsa_DOP1B_circ_0001187	GGAATGTTCTCAGAAAGGAGGA	AATGTTTTCCCTCTTGGAGGT
hsa_ERC2_circ_0124264	CGGATTGAGAGGAGGAAACA	TTGATTGTGCTTGAGGTTGG
hsa_EXOC6B_circ_0009043	TCCGCAAACATTCAGACAAA	GCTTCAGCTCTTCCATTGCT
hsa_EXOSC1_circ_0005887	CCCGAATTCTTGCAGACCTA	ACCTGGGCGGAAACTCTTAT
hsa_FAM120A_circ_0001875	TGTCATTTCATCCACCACATT	CAAGCCATGGAAACCATTCT
hsa_FGD4_circ_0000390	TAGCTGCTCGGAACACTTCA	GCATGTGATGCTGCAAAGTT
hsa_FKBP3_circ_0101874	AAGGCTCGACTGGAGATTGA	GCTGTCTTGGCCACATTTTT
hsa_FUT8_circ_0003028	GTCCAAGATTCTGGCAAAGC	TCAAAGAGATCCTCCTGGTGA
hsa_GBAS_circ_0001709	GAATGAGCCTGTGCCAAGAT	TTCTGTGAGGGCTGGATAGC

hsa_GRIN2B_circ_0097968	CTGAGCCCAAAAGCAGTTGT	TTACGGAAGCTTGCTGTTCA
hsa_HAGH_circ_0105101	CAGGGAGAAGGACCAGTTCA	GCTCCCCGATGCTGTACTT
hsa_HAT1_circ_0008032	TGCTGGTAGCCTGTCAACAA	GCCAGTTTCTTCTCCACTGC
hsa_HIPK3_circ_0000284	TCGGCCAGTCATGTATCAAA	GGGTAGACCAAGACTTGTGAGG
hsa_HMGCLL1_circ_0131944	CAGGTGCTCTTGCTGTTCAC	CATCCCTAGGCCCAACTTCT
hsa_HOMER1_circ_0006916	AATGCATTGCCATTTTCACA	TGTGTTTGGGTCAATTTGGA
hsa_HTT_circ_0001392	TTTGGCAATTTTGCAAATGA	CACACGGTCTTTCTTGGTAGC
hsa_KCNN2_circ_0127664	CCGAGCTTGTGAAAGTTGTTC	CACACACCAGTATTTCCAAGCA
hsa_KDM4C_circ_0001839	ATGGCTACCATGCTGGTTTT	TCAAGTCGTTTTCCATGCTC
hsa_KIAA1841_circ_0007793	GGACCGAGTCAAGTCAAAGG	TGGGCACAGGGTGAAGATAC
hsa_KIDINS220_circ_0005315	ACCGGACTTCATGGCTCATA	CCTCTGCATCTGCCTTCTTC
hsa_KLHL1_circ_0100796	GGAATTCGAGCCTTCGCAGA	TGGAGTCCAAATCACTTTGAGGT
hsa_LMBR1_circ_0005939	GGCTAAATGGCTCCCTGATT	CGATGGCATCTTCATCTTCTT
hsa_LPAR1_circ_0087960	GGCTGCCATCTCTACTTCCA	GTGGATGGGGGAGCTTCATAA
hsa_LRCH1_circ_0002215	GGAAGCATGCCGAAAATTAG	TCCTCCGGATTGTAAACTGC
hsa_LRCH3_circ_0002266	TCCCAAATTGGTAACCTGGA	CCAGAGAAACAAAGTGACATGCT
hsa_LRRC7_circ_0114013	TGGACAAGGAAATCCATTCA	TCCATTGGCCACTAGGAGAT
hsa_MAPK8_circ_0002968	TGTGGAATCAAGCACCTTCA	AAAAATTGTTGTCACGCTTGC
hsa_MAPK9_circ_0001566	TGGAGCTGGATCATGAAAGA	AAGGGTGGGCAAGTTTCAG
hsa_MED12L_circ_0067735	CAACGTGGCTGATCAAGATG	GGCTGGCTGATTATTGAAGC
hsa_NRXN1_circ_0054525	TTCCAGGGTCACCAGTCAGT	GATCCTTTGAACGTGGCAAT
hsa_NTRK2_circ_0139142	CCTGAATGAAAGCAGCAAGA	ACCTTTTCTGGTTTGCGATG
hsa_PAK3_circ_0139566	GTTGGGGACCCAAAGAAAAA	ATCAAACCCCACATGAATCG
hsa_PDE4B_circ_0008433	ACTGCCTTTGACAACGCTTC	TTCAATGCAGTTTGCTGACA
hsa_PHC3_circ_0001359	TGTCACCCGGACATCAAGTA	GGGTAATACTGCCGCTGGTA
hsa_POMT1_circ_0001897	CTGGCCTTGGGAGGTTATTT	GCCCACTGTCATCCAAGAAG
hsa_PPP2R2B_circ_0128256	GCGTGATAAGAGGCCAGAAG	AATTCTCCCGTGTGGTTGAA

hsa_PRKCB_circ_0000682	ACAGGGACGTCCTCATTGTC	GTCACATTTCATCCCCTGGT
hsa_PSD3_circ_0002111	TGCAAGGGGTAAATGAGGGTG	TTCAGTGCTCCCCATTTCAGA
hsa_PSEN1_circ_0003848	AGTTACCTGCACCGTTGTCC	GCTGTCTAAGGACCGCAAAG
hsa_PTK2_circ_0003171	GATGGCTCCAGAGTCAATCAA	CTCACGCTGTCCGAAGTACA
hsa_R3HDM1_circ_0001070	AAGGATCTATGCCCACAACAGG	GACTCTGGGGTTGCTGAACT
hsa_REPS1_circ_0004368	CCATTCAGCCTGATCTAAACG	ACACTGCATCACCAGCAGAA
hsa_RERE_circ_0002158	TAAAGCCCGAGTGGATTCAT	TGACGTTCATGAGGAGATGG
hsa_RIMS1_circ_0132246	GGAGATCCAGCCTTAGTGCC	AGCTTGCTTTTGTGGAAGAGT
hsa_RIMS1_ circ_0132250	AGCAGGTGGAAAGAAACGGA	TGTCTTGTTCGCTCCTCCAC
hsa_RIMS2_circ_0005114	TCTGTCACGGAAAAGTCGCA	TGATCCGGCTACCTGTTTGT
hsa_RMST_circ_0099634	AGGGGCTAGTTGAGGAATGG	CCATTCTGTGCTGAGTGGAG
hsa_RTN4_circ_0054598	GAGGACAGATCACCATCTGCTA	TGCAGAGGAGCGTATCACAG
hsa_SCAF8_circ_0001654	CTTGCGGCTGTAGCTCAGAT	TTTGGGTCATTTTCGCTTTC
hsa_SCLT1_circ_0001439	GAACATGGAAGTGACTAACCAACA	GGGAAAGGCCTCCAATTTT
hsa_SFMBT2_circ_0000211	ATGGCCTCTGAATGGAAATG	CTCGAACCAGTCAAGTCACG
hsa_SLAIN1_circ_0000497	GCTTGCATGGAGCTGGAAATG	ATGTCTACACCACTGCAAAGGA
hsa_SLAIN2_circ_0126525	AAGTGCCAAACGGAGGAATA	AATCCAAAACTTGCCTGCAC
hsa_SLC30A6_circ_0005695	CCGTGCCTGAGCAATAGTTT	TGCACCACATAAGCAGGAAG
hsa_SLC38A1_circ_0000396	CATTATGGGCAGTGGGATTT	GTATGGCCTTCCAGGGTTTT
hsa_SMARCA5_circ_0001445	TGGGCGAAAGTTCACTTAGAA	GAAGCATTTCATCTTTCCCAAT
hsa_STX6_circ_0007905	GGCTGGACAATGTGATGAAG	GCCTGCACAGATGAAGTTGA
hsa_SYT1_circ_0099287	ACAGTGGATTTTGGCCATGT	AAAAGCAGCAGGTCAGGACT
hsa_TMCC1_circ_0001340	GGGAAGCTATTGCTGGGATT	ACCAAAGGCAACTGTTCACC
hsa_TMEFF1_circ_0004425	GGTCAGGGGCAGAAGTTCAC	CTCTTACGTCAGACTCCCTCAC
hsa_TMEM132D_circ_0097876	CAAAGACCGTGAGGAAAGGA	GCAAGGAAAACCTCTGGATG
hsa_TMEM138_circ_0002058	GCTGGAAAAACTCCAACAGC	AGCCTGGAAGACGAAGGTGT
hsa_UBE2K_circ_0002590	CAGAGCCAGATGATCCACAG	GTGTGTCTGGAGGTCCTGCT

hsa_UBXN7_circ_0001380	TGCATAAAGGCAGCTTTGAA	CCGTCGTCTTTTAGGAGCAC
hsa_UIMC1_circ_0001558	CCCACAAAGATTGAACGACA	GCAGCAACACTTTGTGAAGC
hsa_UNC13C_circ_0103896	AAAGCAAATGGCAGAGTTGG	AAACCAGAAGCAAAGCTCCA
hsa_VMP1_circ_0006508	TCTTCTGTTGGGGCTTGGAAC	TTCCATTCTCTGCCATTTCA
hsa_VPS13C_circ_0000607	AAGCACAGGCAGTTACTCAAGA	GCATGGAGTCCAGTGTTCATT
hsa_WDR78_circ_0006677	GAAGACCTGGAAGAACCATCC	TCTGCTTTGATTTGCACCAG
hsa_YY1AP1_circ_0014606	ATTCTGGACCCAGCACAAAG	TCTTCTGGGCCATCATCTTC
hsa_ZFAND6_circ_0000643	TGTGGACAAAGCAGTACCTGA	CCATTTGTACGAGGGTTTCC
hsa_ZMYM4_circ_0011536	GCACCACAGCAGGGACTACT	ATCCTGTTTGATTCGGCATT
hsa_ZNF292_circ_0004058	TTCTTTCCCAGGAACCATTG	CGGGCTTTAACATAACTTTGG
hsa-GAPDH	GCACCACCAACTGCTTAG	GCCATCCACAGTCTTCTG
hsa-U6	CGCTTCGGCAGCACATATAC	TTCACGAATTTGCGTGTCAT

# **Supplemental Table 2.** List of 39 circRNAs not detected in PBMCs

ANKS1B_circ_0007294	KLHL1_circ_0100796	RERE_circ_0002158
ARPP21_circ_0001281	LMBR1_circ_0005939	RIMS1_circ_0132246
CDR1_circ_0001946	LPAR1_circ_0087960	RIMS1_circ_0132250
CNTNAP2_circ_0133631	LRCH1_circ_0002215	<u>RIMS2_circ_0005114</u>
DAB1_circ_0113684	LRRC7_circ_0114013	RMST_circ_0099634
DGKB_circ_0133622	NRXN1_circ_0054525	SCAF8_circ_0001654
ERC2_circ_0124264	NTRK2_circ_0139142	SLC30A6_circ_0005695
EXOSC1_circ_0005887	PAK3_circ_0139566	STX6_circ_0007905
FGD4_circ_0000390	PDE4B_circ_0008433	SYT1_circ_0099287
GRIN2B_circ_0097968	PPP2R2B_circ_0128256	TMEFF1_circ_0004425
HAGH_circ_0105101	PRKCB_circ_0000682	TMEM132D_circ_0097876
HMGCLL1_circ_0131944	PSD3_circ_0002111	UNC13C_circ_0103896
KCNN2_circ_0127664	PTK2_circ_0003171	YY1AP1_circ_0014606

## 472

# 473 Supplemental Table 3. Basic characteristics and comparative PBMC circRNA expression in

474 idiopathic PD patients and healthy controls.

475 CircRNA size and expression in the brain as well as host transcript expression in the body. Means
476 with their respective standard deviation (std) for both groups are shown. Statistically significant
477 differences in comparison to healthy controls (unpaired t-test) are highlighted in grey. Multiple
478 comparison analysis (adjusted *P* values) calculated according to Benjamini-Hochberg false
479 discovery rate method.

oiroDNA ID	Spliced	Expressio n score in	Host gene	Host gene mRNA expression	Mean	(± std)	Unpaire d t-test	Adjusted P values
	length	the human brain*	symbol	in the human body**	нс	iPD	P value	
circ_0001380	247	15326	UBXN7	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.046 (0.348)	-0.016 (0.432)	0.678	0.812
circ_0000284	1099	13889	HIPK3	Ubiquitous, expressed	-0.073	-0.165	0.252	0.603
				least in the brain	(0.443)	(0.435)	0.232	0.005
circ_0001445	269	9354	SMARCA5	Ubiquitous, lower	-0.132	-0.275	0.147	0.415
			EVIC C (D	expression in the brain	(0.565)	(0.504)		
circ_0009043	390	9121	EXOC6B	Ubiquitous, enriched in	-0.061	-0.089	0.701	0.812
circ_0001947	861	9058	AFF2	Ubiquitous, highly enriched in the cerebellum	-0.208 (0.702)	-0.302 (0.531)	0.412	0.706
circ_0002590	336	8841	UBE2K	Ubiquitous, enriched in the cerebellum	-0.062 (0.409)	-0.073 (0.437)	0.895	0.895
circ_0000437	251	8402	CORO1C	Ubiquitous, expressed least in the brain	-0.224 (0.736)	0.007 (0.911)	0.130	0.390
circ_0000497	788	6004	SLAIN1	Brain-specific	-0.096	-0.447	< 0.0001	0.001***
					(0.520)	(0.313)	***	
circ_0054598	2457	5985	RTN4	Ubiquitous, enriched in the brain	-0.165 (0.624)	-0.139 (0.583)	0.815	0.850
circ_0001522	536	5649	CSNK1G3	Ubiquitous, lower	-0.077	-0.190	0.205	0.518
				expression in the brain	(0.452)	(0.505)	0.205	0.518
circ_0001070	307	5300	R3HDM1	Brain-specific	-0.058	0.050	0.204	0.518
					(0.394)	(0.523)	0.204	0.510
circ_0011536	755	4662	ZMYM4	Ubiquitous, expressed	-0.064	-0.093	0.694	0.812
				least in the brain except	(0.417)	(0.406)	0.074	0.012

				cerebellum where expression is somewhat higher than in other tissues				
circ_0000607	606	4056	VPS13C	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.078 (0.449)	0.021 (0.514)	0.266	0.603
circ_0001439	396	3870	SCLT1	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.056 (0.399)	-0.209 (0.429)	0.046*	0.210
circ_0000826	994	3868	ANKRD12	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.059 (0.405)	-0.217 (0.355)	0.024*	0.142
circ_0000211	434	3783	SFMBT2	Ubiquitous	-0.076 (0.457)	-0.239 (0.381)	0.036*	0.189
circ_0002266	378	3204	LRCH3	Ubiquitous, expressed least in the brain except cerebellum where expression is somewhat higher than in other tissues	-0.089 (0.458)	-0.045 (0.433)	0.595	0.782
circ_0002968	499	3123	MAPK8	Ubiquitous, highly enriched in the cerebellum	-0.047 (0.361)	-0.087 (0.476)	0.603	0.782
circ_0000396	522	3086	SLC38A1	Ubiquitous	-0.097 (0.498)	-0.237 (0.472)	0.115	0.380
circ_0001181	1836	3082	BACH1	ubiquitous, expressed least in the brain	-0.203 (0.691)	-0.399 (0.538)	0.086	0.344
circ_0006916	522	3026	HOMER1	Ubiquitous, enriched in the brain	-0.076 (0.452)	-0.292 (0.316)	0.003**	0.036*
circ_0001709	212	2889	GBAS	Ubiquitous, highly enriched in the skeletal muscle	-0.047 (0.354)	-0.060 (0.359)	0.839	0.857
circ_0001897	158	2882	POMT1	Ubiquitous, highly enriched in the cerebellum and testis	-0.069 (0.426)	-0.139 (0.439)	0.375	0.667
circ_0101874	502	2687	FKBP3	Ubiquitous, enriched in the brain	-0.059 (0.395)	-0.136 (0.482)	0.347	0.640
circ_0002454	350	2511	DNAJC6	Brain-specific	-0.247 (0.728)	-0.027 (0.806)	0.119	0.380
circ_0001558	397	2476	UIMC1	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.095 (0.498)	0.028 (0.497)	0.459	0.711

circ_0001187	301	2263	DOP1B	Ubiquitous, highly enriched in the cerebellum	-0.071 (0.440)	-0.265 (0.282)	0.005**	0.038*
circ_0006508	440	2229	VMP1	Ubiquitous, expressed least in the brain	-0.058 (0.384)	-0.031 (0.402)	0.711	0.812
circ_0006677	473	2190	WDR78	Testis, lung	-0.072 (0.439)	-0.051 (0.492)	0.801	0.850
circ_0008032	302	2153	HAT1	Ubiquitous, expressed least in the brain	-0.133 (0.579)	-0.204 (0.526)	0.482	0.723
circ_0043837	444	1892	ATP6V0A1	Ubiquitous, highly enriched in the brain	-0.142 (0.611)	-0.250 (0.597)	0.334	0.640
circ_0004368	352	1882	REPS1	Ubiquitous, highly enriched in the cerebellum	-0.076 (0.455)	-0.299 (0.313)	0.002**	0.036*
circ_0005315	308	1820	KIDINS220	Ubiquitous, enriched in the cerebellum	-0.149 (0.554)	-0.194 (0.438)	0.628	0.793
circ_0002058	248	1775	TMEM138	ubiquitous, expressed least in the brain	-0.055 (0.379)	0.028 (0.465)	0.286	0.603
circ_0001566	497	1745	MAPK9	Ubiquitous, enriched in the brain	-0.066 (0.425)	-0.284 (0.352)	0.002**	0.036*
circ_0007793	284	1645	KIAA1841	Ubiquitous, somewhat brain-enriched	-0.141 (0.591)	-0.168 (0.556)	0.793	0.850
circ_0001340	251	1631	TMCC1	Ubiquitous, enriched in the cerebellum	-0.054 (0.380)	-0.108 (0.389)	0.443	0.711
circ_0007162	1121	1526	AGTPBP1	Ubiquitous, somewhat brain-enriched	-0.103 (0.524)	-0.317 (0.434)	0.017*	0.113
circ_0003848	222	1430	PSEN1	Ubiquitous, highly enriched in the spinal cord	-0.054 (0.388)	-0.241 (0.308)	0.004**	0.038*
circ_0004058	370	1422	ZNF292	Ubiquitous, expressed least in the brain except cerebellum where expression is similar to other tissues	-0.095 (0.491)	-0.045 (0.479)	0.577	0.782
circ_0001875	556	1345	FAM120A	Ubiquitous, expressed least in the brain	-0.098 (0.504)	-0.196 (0.500)	0.289	0.603
circ_0003028	430	1336	FUT8	Ubiquitous, highly enriched in the spinal cord	-0.270 (0.792)	-0.309 (0.654)	0.850	0.850
circ_0001839	292	1280	KDM4C	Ubiquitous, highly enriched in the cerebellum	-0.066 (0.418)	-0.115 (0.482)	0.557	0.782
circ_0001392	484	1270	HTT	Ubiquitous, enriched in the cerebellum	-0.060 (0.384)	-0.019 (0.453)	0.602	0.782
circ_0067735	457	952	MED12L	Adrenal glands, brain, cervix, pituitary and testis	-0.477 (1.100)	-0.124 (1.202)	0.096	0.354
circ_0000643	381	761	ZFAND6	Ubiquitous, expressed least in the brain	-0.090 (0.477)	-0.173 (0.467)	0.341	0.640
circ_0126525	971	720	SLAIN2	Ubiquitous, expressed least in the brain	-0.075 (0.450)	0.125 (0.628)	0.048*	0.210
circ_0001359	505	709	РНС3	Ubiquitous, expressed least in the brain	-0.060 (0.403)	-0.118 (0.434)	0.454	0.711

- 481 \*According to Rybak et al.
- 482 \*\* According to GTEx portal.

483

# 484 Supplemental Table 4. Correlation between relative circRNA expression and sex, age, age-

485 at-onset, PD duration, HY, UPDRS and MMSE scores and LEDD of PD patients.

circRNA	Sex U score (P value)	Age Rho (P value)	Age-at- onset Rho (P value)	PD duration Rho (P value)	UPDRS III Rho (P value)	MMSE Rho (P value)	HY Rho (P value)	LEDD Rho (P value)
UBXN7_circ	0.027	-0.012	-0.142	0.041	0.143	0.096	0.113	0.055
_0001380	(0.8684)	(0.8949)	(0.2831)	(0.7579)	(0.2788)	(0.4674)	(0.3953)	(0.6791)
HIPK3_circ	1.694	0.004	-0.129	-0.063	-0.036	0.090	-0.052	0.100
_0000284	(0.1930)	(0.9627)	(0.3266)	(0.6303)	(0.7847)	(0.4924)	(0.6943)	(0.4450)
SMARCA5_	0.778	-0.035	-0.119	-0.174	0.018	0.082	0.005	0.006
circ_0001445	(0.3776)	(0.7078)	(0.3663)	(0.1847)	(0.8931)	(0.5321)	(0.9704)	(0.9643)
EXO6CB_circ	1.129	0.142	0.225	-0.116	-0.014	-0.021	-0.066	-0.024
_0009043	(0.2880)	(0.1215)	(0.0836)	(0.3793)	(0.9165)	(0.8736)	(0.6187)	(0.8551)
AFF2_circ	0.011	0.107	0.101	-0.036	0.050	-0.048	-0.138	0.156
_0001947	(0.9159)	(0.2446)	(0.4418)	(0.7871)	(0.7055)	(0.7130)	(0.2917)	(0.2334)
UBE2K_circ	0.010	-0.035	-0.143	-0.187	-0.167	0.065	-0.012	-0.139
_0002590	(0.9208)	(0.7022)	(0.2773)	(0.1535)	(0.2024)	(0.6205)	(0.9295)	(0.2898)
CORO1C_circ	0.035	-0.089	-0.390	0.211	0.090	0.039	0.019	0.183
_0000437	(0.8521)	(0.3313)	(0.0021)	(0.1050)	(0.4928)	(0.7691)	(0.8856)	(0.1618)
SLAIN1_circ	0.026	-0.098	-0.085	-0.109	0.094	0.257	0.132	0.050
_0000497	(0.8717)	(0.2870)	(0.5188)	(0.4071)	(0.4771)	(0.0472)	(0.3146)	(0.7061)
RTN4_circ	3.005	0.035	-0.203	-0.073	-0.033	0.077	-0.016	0.027
_0054598	(0.0830)	(0.7015)	(0.1191)	(0.5807)	(0.8049)	(0.5578)	(0.9048)	(0.8353)
CSNK1G3_	3.347	-0.049	0.083	-0.217	-0.018	0.172	-0.088	-0.115
circ_0001522	(0.0673)	(0.5978)	(0.5300)	(0.0987)	(0.8931)	(0.1924)	(0.5066)	(0.3837)
R3HDM1_	0.078	0.010	0.033	-0.127	-0.224	0.061	-0.156	-0.153
circ_0001070	(0.7798)	(0.9160)	(0.8001)	(0.3322)	(0.0850)	(0.6445)	(0.2326)	(0.2434)
ZMYM4_circ	3.556	-0.085	-0.044	-0.341	-0.123	0.122	0.000	-0.081
_0011536	(0.0593)	(0.3584)	(0.7413)	(0.0078)	(0.3479)	(0.3540)	(0.9976)	(0.5403)

VPS13C circ	0.001	0.049	0.018	-0.048	-0.073	-0.204	0.090	-0.058
_0000607	(0.9802)	(0.5951)	(0.8923)	(0.7134)	(0.5790)	(0.1181)	(0.4930)	(0.6610)
SCLT1_circ	0.028	0.016	-0.159	-0.037	0.094	0.048	0.055	0.184
_0001439	(0.8668)	(0.8636)	(0.2264)	(0.7774)	(0.4769)	(0.7169)	(0.6761)	(0.1589)
ANKRD12_	0.285	0.008	-0.091	0.016	0.090	-0.023	0.165	0.116
circ_0000826	(0.5931)	(0.9346)	(0.4876)	(0.9014)	(0.4944)	(0.8612)	(0.2071)	(0.3755)
SFMBT2_circ	0.519	0.100	0.008	-0.114	0.053	0.244	0.092	0.003
_0000211	(0.4711)	(0.2778)	(0.9543)	(0.3873)	(0.6898)	(0.0598)	(0.4864)	(0.9828)
LRCH3_circ	0.556	-0.042	-0.094	-0.236	-0.104	0.087	0.070	-0.061
_0002266	(0.4559)	(0.6471)	(0.4739)	(0.0692)	(0.4283)	(0.5074)	(0.5965)	(0.6453)
MAPK8_circ	0.846	-0.064	0.037	-0.163	0.040	0.096	0.115	-0.090
_0002968	(0.3578)	(0.4898)	(0.7785)	(0.2146)	(0.7634)	(0.4648)	(0.3814)	(0.4943)
SLC38A1_	0.062	-0.111	0.207	-0.149	0.024	0.087	0.004	-0.135
circ_0000396	(0.8037)	(0.2284)	(0.1124)	(0.2565)	(0.8558)	(0.5068)	(0.9766)	(0.3040)
BACH1_circ	3.978	-0.133	-0.110	-0.028	0.070	0.070	0.066	0.254
_0001181	(0.0461)	(0.1488)	(0.4034)	(0.8333)	(0.5948)	(0.5932)	(0.6146)	(0.0498)
HOMER1_	0.102	-0.112	-0.040	-0.090	0.099	0.068	0.157	0.032
circ_0006916	(0.7490)	(0.2253)	(0.7623)	(0.4928)	(0.4499)	(0.6068)	(0.2318)	(0.8105)
GBAS_circ	0.892	-0.041	-0.066	-0.001	0.111	0.201	0.185	0.025
_0001709	(0.3450)	(0.6604)	(0.6138)	(0.9951)	(0.4003)	(0.1244)	(0.1566)	(0.8487)
POMT1_circ	1.293	0.032	0.002	-0.130	-0.006	-0.095	0.012	-0.011
_0001897	(0.2555)	(0.7285)	(0.9851)	(0.3239)	(0.9630)	(0.4723)	(0.9301)	(0.9336)
FKBP3_circ	0.030	-0.073	-0.009	-0.142	0.104	0.111	0.016	0.050
_0101874	(0.8633)	(0.4314)	(0.9472)	(0.2839)	(0.4318)	(0.4040)	(0.9041)	(0.7091)
DNAJC6_circ	0.575	-0.107	-0.379	0.000	-0.011	0.019	-0.008	0.078
_0002454	(0.4485)	(0.2443)	(0.0028)	(0.9985)	(0.9352)	(0.8864)	(0.9514)	(0.5516)
U1MC1_circ	2.384	-0.010	-0.070	-0.223	-0.181	0.083	-0.104	-0.035
_0001558	(0.1226)	(0.9113)	(0.5960)	(0.0868)	(0.1657)	(0.5273)	(0.4310)	(0.7909)
DOP1B_circ	0.812	-0.035	0.020	-0.101	-0.147	-0.075	-0.156	-0.267
_0001187	(0.3676)	(0.7063)	(0.8778)	(0.4416)	(0.2623)	(0.5711)	(0.2354)	(0.0396)
VMP1_circ	0.785	-0.071	-0.188	-0.123	-0.053	0.166	0.046	-0.112
_0006508	(0.3756)	(0.4460)	(0.1534)	(0.3538)	(0.6923)	(0.2081)	(0.7298)	(0.3980)
WDR78_circ	0.547	-0.086	-0.252	-0.074	-0.037	0.071	0.044	0.001
_0006677	(0.4596)	(0.3541)	(0.0545)	(0.5794)	(0.7812)	(0.5919)	(0.7407)	(0.9918)
HAT1_circ	4.783	-0.039	-0.098	-0.131	0.018	0.100	0.138	0.030
_0008032	(0.0287)	(0.6710)	(0.4550)	(0.3176)	(0.8914)	(0.4488)	(0.2922)	(0.8196)

ATP6V0A1_	0.010	0.048	-0.111	0.095	-0.001	-0.008	-0.072	0.070
circ_0043837	(0.9208)	(0.6025)	(0.3978)	(0.4719)	(0.9958)	(0.9523)	(0.5843)	(0.5971)
REPS1_circ	0.363	0.012	0.108	-0.206	-0.009	-0.148	-0.023	-0.054
_0004368	(0.5467)	(0.8933)	(0.4099)	(0.1135)	(0.9453)	(0.2587)	(0.8642)	(0.6831)
KIDINS220_	4.019	0.010	-0.093	-0.076	0.058	0.227	0.036	0.020
circ_0005315	(0.0450)	(0.9103)	(0.4845)	(0.5681)	(0.6643)	(0.0833)	(0.7864)	(0.8785)
TMEM138_	0.020	0.032	-0.008	-0.030	0.014	-0.043	0.068	0.030
circ_0002058	(0.8864)	(0.7304)	(0.9521)	(0.8227)	(0.9144)	(0.7471)	(0.6034)	(0.8221)
MAPK9_circ	1.954	0.044	-0.119	0.063	0.062	0.202	0.057	-0.010
_0001566	(0.1621)	(0.6357)	(0.3663)	(0.6301)	(0.6389)	(0.1208)	(0.6662)	(0.9406)
KIAA1841_	0.034	-0.014	-0.179	-0.027	0.089	0.025	0.050	0.244
circ_0007793	(0.8546)	(0.8824)	(0.1715)	(0.8372)	(0.4983)	(0.8473)	(0.7058)	(0.0601)
TMCC1_circ	0.053	-0.006	-0.104	-0.049	0.026	0.093	0.045	0.049
_0001340	(0.8185)	(0.9453)	(0.4335)	(0.7133)	(0.8473)	(0.4816)	(0.7331)	(0.7141)
AGTPBP1_	0.068	0.033	-0.047	-0.076	0.168	0.156	0.110	0.264
circ_0007162	(0.7941)	(0.7198)	(0.7215)	(0.5616)	(0.1995)	(0.2330)	(0.4023)	(0.0413)
PSEN1_circ	0.148	0.002	-0.263	0.012	0.077	0.160	0.010	0.244
_0003848	(0.7001)	(0.9865)	(0.0424)	(0.9249)	(0.5594)	(0.2218)	(0.9394)	(0.0606)
ZNF292_circ	0.121	-0.020	-0.089	-0.232	-0.022	0.077	-0.038	-0.074
_0004058	(0.7283)	(0.8305)	(0.5008)	(0.0770)	(0.8662)	(0.5620)	(0.7733)	(0.5774)
FAM120A_	0.047	-0.082	-0.237	-0.145	-0.070	0.129	-0.041	-0.009
circ_0001875	(0.8279)	(0.3747)	(0.0687)	(0.2675)	(0.5942)	(0.3253)	(0.7551)	(0.9473)
FUT8_circ	0.493	-0.074	-0.214	0.029	-0.040	0.072	-0.094	-0.114
_0003028	(0.4826)	(0.4238)	(0.1004)	(0.8233)	(0.7600)	(0.5852)	(0.4761)	(0.3875)
KDM4C_circ	0.030	0.070	0.122	-0.183	-0.177	0.069	-0.153	-0.121
_0001839	(0.8619)	(0.4462)	(0.3525)	(0.1627)	(0.1753)	(0.6028)	(0.2436)	(0.3555)
HTT_circ	1.317	-0.092	-0.045	-0.101	0.078	0.118	0.054	-0.006
_0001392	(0.2512)	(0.3232)	(0.7327)	(0.4470)	(0.5564)	(0.3754)	(0.6859)	(0.9664)
MED12L_circ	1.103	-0.137	-0.415	0.221	0.066	0.050	0.008	0.246
_0067735	(0.2937)	(0.1368)	(0.0010)	(0.0893)	(0.6178)	(0.7037)	(0.9512)	(0.0580)
ZFAND6_circ	4.280	-0.053	-0.138	-0.148	-0.046	0.098	-0.029	-0.108
_0000643	(0.0386)	(0.5659)	(0.2939)	(0.2585)	(0.7246)	(0.4573)	(0.8284)	(0.4101)
SLAIN2_circ	0.623	0.015	-0.060	-0.135	-0.100	0.096	-0.043	-0.039
_0126525	(0.4301)	(0.8669)	(0.6462)	(0.3030)	(0.4489)	(0.4651)	(0.7458)	(0.7653)
PHC3_circ	0.418	-0.003	-0.064	-0.217	-0.068	0.139	-0.037	-0.077
_0001359	(0.5182)	(0.9738)	(0.6282)	(0.0951)	(0.6062)	(0.2897)	(0.7778)	(0.5598)

488	Significance Supplemental Table 5. KEGG and GOslim categories that are mostly
489	deregulated in idiopathic PD. Gene union of the targets of the five miRNAs (miR-516b-5p, miR-
490	526b-5p, miR-578, miR-659-3p, miR-1197) sequestered by half or more of the deregulated PD
491	circRNAs in PD versus (A) KEGG and (B) GOslim categories created by the DIANA-miRPath
492	v3.0 interface using default values ( <i>p</i> -value threshold 0.05, microT-CDS threshold 0.8).

Α

KEGG pathway	P value	# genes	# miRNAs
Thyroid hormone signaling pathway	0.001458	24	5
Cell cycle	0.009263	25	5
Regulation of actin cytoskeleton	0.014546	42	5
Rap1 signaling pathway	0.01546	35	5
Phosphatidylinositol signaling system	0.015883	16	4
MAPK signaling pathway	0.015883	46	5
FoxO signaling pathway	0.015883	26	5

 B

GOslim category	P value	# genes	# miRNAs
Organelle	1.13E-78	1143	5
Cellular nitrogen compound metabolic process	6.05E-47	587	5
Cellular protein modification process	3.93E-19	283	5
Nucleoplasm	2.34E-13	159	5
Enzyme binding	2.34E-13	168	5

Protein complex	4.38E-11	411	5
Protein binding transcription factor activity	6.74E-10	70	5
Cytoskeletal protein binding	3.91E-09	102	5
Cell death	7.91E-08	112	5
RNA binding	6.93E-07	207	5
Nucleic acid binding transcription factor activity	7.74E-07	112	5
Macromolecular complex assembly	3.06E-05	95	5
Response to stress	3.72E-05	225	5
Membrane organization	4.89E-05	65	5
Cytoskeleton organization	0.000178	80	5

499

#### 500 **REFERENCES**

Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's
 disease. Movement disorders : official journal of the Movement Disorder Society
 2015;30(12):1591-1601.

Bhidayasiri R, Martinez-Martin P. Clinical Assessments in Parkinson's Disease: Scales and
 Monitoring. International review of neurobiology 2017;132:129-182.

506 3. Miller DB, O'Callaghan JP. Biomarkers of Parkinson's disease: present and future.

507 Metabolism: clinical and experimental 2015;64(3 Suppl 1):S40-46.

Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs
with regulatory potency. Nature 2013;495(7441):333-338.

5. Salzman J, Gawad C, Wang PL, Lacayo N, Brown PO. Circular RNAs are the predominant

transcript isoform from hundreds of human genes in diverse cell types. PloS one 2012;7(2):e30733.

512 6. Zaphiropoulos PG. Circular RNAs from transcripts of the rat cytochrome P450 2C24 gene:

513 correlation with exon skipping. Proceedings of the National Academy of Sciences of the United

514 States of America 1996;93(13):6536-6541.

515 7. Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and

associated with ALU repeats. Rna 2013;19(2):141-157.

- 517 8. Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene
  518 expression control. Nature 2011;473(7347):337-342.
- 519 9. Abdelmohsen K, Panda AC, Munk R, et al. Identification of HuR target circular RNAs

uncovers suppression of PABPN1 translation by CircPABPN1. RNA biology 2017;14(3):361-369.

10. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient
microRNA sponges. Nature 2013;495(7441):384-388.

523 11. Zimmerman AJ, Hafez AK, Amoah SK, et al. A psychiatric disease-related circular RNA

524 controls synaptic gene expression and cognition. Molecular psychiatry 2020.

- Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the
  nucleus. Nature structural & molecular biology 2015;22(3):256-264.
- 527 13. Zhang Y, Zhang XO, Chen T, et al. Circular intronic long noncoding RNAs. Molecular
  528 cell 2013;51(6):792-806.
- 14. Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with premRNA splicing. Molecular cell 2014;56(1):55-66.
- 15. Koh W, Gonzalez V, Natarajan S, Carter R, Brown PO, Gawad C. Dynamic ASXL1 Exon
  Skipping and Alternative Circular Splicing in Single Human Cells. PloS one
  2016;11(10):e0164085.

16. You X, Vlatkovic I, Babic A, et al. Neural circular RNAs are derived from synaptic genes
and regulated by development and plasticity. Nature neuroscience 2015;18(4):603-610.

536 17. Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout
537 development and ageing in the rat. Scientific reports 2019;9(1):2564.

- 18. Rybak-Wolf A, Stottmeister C, Glazar P, et al. Circular RNAs in the Mammalian Brain
- Are Highly Abundant, Conserved, and Dynamically Expressed. Molecular cell 2015;58(5):870885.
- 541 19. Mehta SL, Dempsey RJ, Vemuganti R. Role of circular RNAs in brain development and
  542 CNS diseases. Progress in neurobiology 2020;186:101746.
- 543 20. Lukiw WJ. Circular RNA (circRNA) in Alzheimer's disease (AD). Frontiers in genetics
  544 2013;4:307.
- 545 21. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir546 153. The Journal of biological chemistry 2010;285(17):12726-12734.
- 547 22. Zhao Y, Alexandrov PN, Jaber V, Lukiw WJ. Deficiency in the Ubiquitin Conjugating
- 548 Enzyme UBE2A in Alzheimer's Disease (AD) is Linked to Deficits in a Natural Circular miRNA-
- 549 7 Sponge (circRNA; ciRS-7). Genes 2016;7(12).
- 550 23. Hanan M, Simchovitz A, Yayon N, et al. A Parkinson's disease CircRNAs Resource reveals
- a link between circSLC8A1 and oxidative stress. EMBO molecular medicine 2020:e11942.
- 552 24. Paschou M, Doxakis E. Neurofibromin 1 Is a miRNA Target in Neurons. PloS one
  553 2012;7(10):e46773.
- 25. Paschou M, Maier L, Papazafiri P, et al. Neuronal microRNAs modulate TREK two-pore
- domain K(+) channel expression and current density. RNA biology 2020;17(5):651-662.

- 556 26. Tan CL, Plotkin JL, Veno MT, et al. MicroRNA-128 governs neuronal excitability and
  557 motor behavior in mice. Science 2013;342(6163):1254-1258.
- 558 27. Zhang W, Kim PJ, Chen Z, et al. MiRNA-128 regulates the proliferation and neurogenesis
- of neural precursors by targeting PCM1 in the developing cortex. eLife 2016;5.
- 560 28. Iturria-Medina Y, Khan AF, Adewale Q, Shirazi AH, Alzheimer's Disease Neuroimaging
- 561 I. Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in
- neurodegeneration. Brain : a journal of neurology 2020;143(2):661-673.
- 563 29. Naughton BJ, Duncan FJ, Murrey DA, et al. Blood genome-wide transcriptional profiles
- reflect broad molecular impairments and strong blood-brain links in Alzheimer's disease. Journal
- 565 of Alzheimer's disease : JAD 2015;43(1):93-108.
- 56630.Pinho R, Guedes LC, Soreq L, et al. Gene Expression Differences in Peripheral Blood of
- 567 Parkinson's Disease Patients with Distinct Progression Profiles. PloS one 2016;11(6):e0157852.
- 56831.Soreq L, Bergman H, Israel Z, Soreq H. Exon arrays reveal alternative splicing aberrations
- in Parkinson's disease leukocytes. Neuro-degenerative diseases 2012;10(1-4):203-206.
- 570 32. van Heerden JH, Conesa A, Stein DJ, Montaner D, Russell V, Illing N. Parallel changes in
- 571 gene expression in peripheral blood mononuclear cells and the brain after maternal separation in
- the mouse. BMC research notes 2009;2:195.
- Soreq L, Salomonis N, Bronstein M, et al. Small RNA sequencing-microarray analyses in
  Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain
  region transcriptomes. Frontiers in molecular neuroscience 2013;6:10.
- 576 34. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia:
- 577 recommendations from the movement disorder society task force. Movement disorders : official
- 578 journal of the Movement Disorder Society 2007;22(16):2314-2324.

- 579 35. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of
- 580 levodopa dose equivalency reporting in Parkinson's disease. Movement disorders : official journal
- 581 of the Movement Disorder Society 2010;25(15):2649-2653.
- 582 36. Maass PG, Glazar P, Memczak S, et al. A map of human circular RNAs in clinically
- relevant tissues. Journal of molecular medicine 2017;95(11):1179-1189.
- 37. Dube U, Del-Aguila JL, Li Z, et al. An atlas of cortical circular RNA expression in
  Alzheimer disease brains demonstrates clinical and pathological associations. Nature neuroscience
  2019;22(11):1903-1912.
- 587 38. Gokool A, Anwar F, Voineagu I. The Landscape of Circular RNA Expression in the
  588 Human Brain. Biological psychiatry 2020;87(3):294-304.
- 589 39. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. 590 CircInteractome: A web tool for exploring circular RNAs and their interacting proteins and 591 microRNAs. RNA biology 2016;13(1):34-42.
- 40. Xia S, Feng J, Chen K, et al. CSCD: a database for cancer-specific circular RNAs. Nucleic
  acids research 2018;46(D1):D925-D929.
- 41. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-
- ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic acids
  research 2014;42(Database issue):D92-97.
- 597 42. Vlachos IS, Zagganas K, Paraskevopoulou MD, et al. DIANA-miRPath v3.0: deciphering
- 598 microRNA function with experimental support. Nucleic acids research 2015;43(W1):W460-466.
- 599 43. Ravanidis S, Bougea A, Papagiannakis N, et al. Circulating Brain-enriched MicroRNAs
- 600 for detection and discrimination of idiopathic and genetic Parkinson's disease. Movement disorders
- 601 : official journal of the Movement Disorder Society 2020;35(3):457-467.

- 44. Dzamko N, Zhou J, Huang Y, Halliday GM. Parkinson's disease-implicated kinases in the
  brain; insights into disease pathogenesis. Frontiers in molecular neuroscience 2014;7:57.
- 45. Waetzig V, Zhao Y, Herdegen T. The bright side of JNKs-Multitalented mediators in
  neuronal sprouting, brain development and nerve fiber regeneration. Progress in neurobiology
  2006;80(2):84-97.
- 46. Jardin I, Lopez JJ, Berna-Erro A, Salido GM, Rosado JA. Homer proteins in Ca(2)(+)
  entry. IUBMB life 2013;65(6):497-504.
- disease: association study with psychotic symptoms. Neuropsychobiology 2009;59(4):239-245.
- 611 48. van der Vaart B, Franker MA, Kuijpers M, et al. Microtubule plus-end tracking proteins
- SLAIN1/2 and ch-TOG promote axonal development. The Journal of neuroscience : the official
  journal of the Society for Neuroscience 2012;32(42):14722-14728.
- 49. Harripaul R, Vasli N, Mikhailov A, et al. Mapping autosomal recessive intellectual
  disability: combined microarray and exome sequencing identifies 26 novel candidate genes in 192
  consanguineous families. Molecular psychiatry 2018;23(4):973-984.
- 617 50. McGough IJ, de Groot REA, Jellett AP, et al. SNX3-retromer requires an evolutionary
  618 conserved MON2:DOPEY2:ATP9A complex to mediate Wntless sorting and Wnt secretion.
- 619 Nature communications 2018;9(1):3737.
- 51. Zhao SB, Dean N, Gao XD, Fujita M. MON2 Guides Wntless Transport to the Golgi
  through Recycling Endosomes. Cell structure and function 2020;45(1):77-92.
- 52. Lopes C, Chettouh Z, Delabar JM, Rachidi M. The differentially expressed C21orf5 gene

623 in the medial temporal-lobe system could play a role in mental retardation in Down syndrome and

transgenic mice. Biochemical and biophysical research communications 2003;305(4):915-924.

625	53. Rachidi M, Delezoide AL, Delabar JM, Lopes C. A quantitative assessment of gene
626	expression (QAGE) reveals differential overexpression of DOPEY2, a candidate gene for mental
627	retardation, in Down syndrome brain regions. International journal of developmental neuroscience
628	: the official journal of the International Society for Developmental Neuroscience 2009;27(4):393-
629	398.

54. Swaminathan S, Huentelman MJ, Corneveaux JJ, et al. Analysis of copy number variation
in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified
individuals. PloS one 2012;7(12):e50640.

55. Swaminathan S, Shen L, Kim S, et al. Analysis of copy number variation in Alzheimer's

disease: the NIALOAD/ NCRAD Family Study. Current Alzheimer research 2012;9(7):801-814.

56. Dergai O, Novokhatska O, Dergai M, et al. Intersectin 1 forms complexes with SGIP1 and
Reps1 in clathrin-coated pits. Biochemical and biophysical research communications
2010;402(2):408-413.

57. Drecourt A, Babdor J, Dussiot M, et al. Impaired Transferrin Receptor Palmitoylation and
Recycling in Neurodegeneration with Brain Iron Accumulation. American journal of human
genetics 2018;102(2):266-277.

58. Bagyinszky E, Youn YC, An SS, Kim S. The genetics of Alzheimer's disease. Clinical
interventions in aging 2014;9:535-551.

59. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in
brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid
precursor protein genes. The American journal of pathology 1998;153(5):1365-1370.

646 60. Deaton CA, Johnson GVW. Presenilin 1 Regulates Membrane Homeostatic Pathways that

are Dysregulated in Alzheimer's Disease. Journal of Alzheimer's disease : JAD 2020.

648	61.	Gatto EM, Rojas GJ, Nemirovsky SI, et al. A novel mutation in PSEN1 (p.Arg41Ser) in an
649	Arger	ntinian woman with early onset Parkinsonism. Parkinsonism & related disorders 2020;77:21-
650	25.	

62. Ravanidis S, Bougea A, Papagiannakis N, et al. Validation of differentially expressed
brain-enriched microRNAs in the plasma of PD patients. Annals of clinical and translational
neurology 2020.

654 63. Abramzon YA, Fratta P, Traynor BJ, Chia R. The Overlapping Genetics of Amyotrophic
655 Lateral Sclerosis and Frontotemporal Dementia. Frontiers in neuroscience 2020;14:42.

656 64. Doxakis E. RNA binding proteins: a common denominator of neuronal function and657 dysfunction. Neuroscience bulletin 2014;30(4):610-626.

- 658 65. Egorova PA, Bezprozvanny IB. Molecular Mechanisms and Therapeutics for
  659 Spinocerebellar Ataxia Type 2. Neurotherapeutics : the journal of the American Society for
  660 Experimental NeuroTherapeutics 2019;16(4):1050-1073.
- 66. Ravanidis S, Doxakis E. RNA-Binding Proteins Implicated in Mitochondrial Damage and
  Mitophagy. Frontiers in cell and developmental biology 2020;8:372.

663 67. Ravanidis S, Kattan FG, Doxakis E. Unraveling the Pathways to Neuronal Homeostasis

and Disease: Mechanistic Insights into the Role of RNA-Binding Proteins and Associated Factors.

- 665 International journal of molecular sciences 2018;19(8).
- 666 68. Salcedo-Arellano MJ, Dufour B, McLennan Y, Martinez-Cerdeno V, Hagerman R. Fragile

K syndrome and associated disorders: Clinical aspects and pathology. Neurobiology of disease
2020;136:104740.

- 669 69. Kim JM, Hong S, Kim GP, et al. Importance of low-range CAG expansion and CAA
- 670 interruption in SCA2 Parkinsonism. Archives of neurology 2007;64(10):1510-1518.

70. Wang C, Xu Y, Feng X, et al. Linkage analysis and whole-exome sequencing exclude extra
mutations responsible for the parkinsonian phenotype of spinocerebellar ataxia-2. Neurobiology
of aging 2015;36(1):545 e541-547.
71. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism
in ethnic Chinese. Neurology 2000;55(6):800-805.

Furtado S, Payami H, Lockhart PJ, et al. Profile of families with parkinsonism-predominant
spinocerebellar ataxia type 2 (SCA2). Movement disorders : official journal of the Movement
Disorder Society 2004;19(6):622-629.

679 73. Martens LH, Zhang J, Barmada SJ, et al. Progranulin deficiency promotes
680 neuroinflammation and neuron loss following toxin-induced injury. The Journal of clinical
681 investigation 2012;122(11):3955-3959.

Piscopo P, Grasso M, Fontana F, et al. Reduced miR-659-3p Levels Correlate with
Progranulin Increase in Hypoxic Conditions: Implications for Frontotemporal Dementia. Frontiers
in molecular neuroscience 2016;9:31.

Rademakers R, Eriksen JL, Baker M, et al. Common variation in the miR-659 binding-site
of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human molecular
genetics 2008;17(23):3631-3642.

76. Xu J, Xilouri M, Bruban J, et al. Extracellular progranulin protects cortical neurons from
toxic insults by activating survival signaling. Neurobiology of aging 2011;32(12):2326 e23252316.

77. Yin F, Banerjee R, Thomas B, et al. Exaggerated inflammation, impaired host defense, and
neuropathology in progranulin-deficient mice. The Journal of experimental medicine
2010;207(1):117-128.

- 694 78. Bucher M, Fanutza T, Mikhaylova M. Cytoskeletal makeup of the synapse: Shaft versus
  695 spine. Cytoskeleton 2020;77(3-4):55-64.
- 696 79. Pinho J, Marcut C, Fonseca R. Actin remodeling, the synaptic tag and the maintenance of
- 697 synaptic plasticity. IUBMB life 2020;72(4):577-589.
- 698 80. Rai SN, Dilnashin H, Birla H, et al. The Role of PI3K/Akt and ERK in Neurodegenerative
- Disorders. Neurotoxicity research 2019;35(3):775-795.
- 81. Santo EE, Paik J. FOXO in Neural Cells and Diseases of the Nervous System. Current
- topics in developmental biology 2018;127:105-118.
- 702 82. Junqueira SC, Centeno EGZ, Wilkinson KA, Cimarosti H. Post-translational modifications
- of Parkinson's disease-related proteins: Phosphorylation, SUMOylation and Ubiquitination.
- Biochimica et biophysica acta Molecular basis of disease 2019;1865(8):2001-2007.
- 705 83. Pajarillo E, Rizor A, Lee J, Aschner M, Lee E. The role of posttranslational modifications
- of alpha-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental
- factors. Biochimica et biophysica acta Molecular basis of disease 2019;1865(8):1992-2000.
- 70884.Calogero AM, Mazzetti S, Pezzoli G, Cappelletti G. Neuronal microtubules and proteins
- linked to Parkinson's disease: a relevant interaction? Biological chemistry 2019;400(9):1099-1112.
- 710 85. Pellegrini L, Wetzel A, Granno S, Heaton G, Harvey K. Back to the tubule: microtubule
- dynamics in Parkinson's disease. Cellular and molecular life sciences : CMLS 2017;74(3):409-
- 712 434.
- 713